Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.48 |
| ▸ | GAA | P10253 | 3/20 | 0.48 |
| ▸ | LMNA | P02545 | 2/20 | 0.48 |
| ▸ | POLB | P06746 | 2/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | APAF1 | O14727 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | BLM | P54132 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | CTSK | P43235 | 3/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | IDO1 | P14902 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11657181 | 0.98 | MAPT (0.47) | MAPTGAALMNAPOLBKDM4E | |
| SCHEMBL28188825 | 0.98 | MAPT (0.47) | MAPTGAALMNAPOLBKDM4E | |
| SCHEMBL3919638 | 0.98 | MAPT (0.47) | MAPTGAALMNAPOLBKDM4E | |
| SCHEMBL2184658 | 0.95 | MAPT (0.44) | MAPTGAALMNAPOLBKDM4E | |
| SCHEMBL2184221 | 0.91 | MAPT (0.38) | MAPTGAALMNAPOLBKDM4E | |
| SCHEMBL11526739 | 0.83 | MAPT (0.63) | MAPTGAALMNAPOLBKDM4E | |
| SCHEMBL2185080 | 0.81 | MAPK1 (0.44) | MAPTGAALMNAPOLBMAPK1 | |
| SCHEMBL27896072 | 0.81 | HRH3 (0.40) | MAPK1CTSK | |
| SCHEMBL7535042 | 0.81 | CNR2 (0.37) | MAPTGAALMNAPOLBALDH1A1 | |
| SCHEMBL3400048 | 0.80 | MAPT (0.61) | MAPTGAALMNAPOLBKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110166132-A1 | Gamma Secretase Modulators | AMGEN INC. (US) | 2011-07-07 | — | — | US | claimed |
| EP-2231602-A1 | GAMMA SECRETASE MODULATORS | Amgen, Inc (US) | 2010-09-29 | — | — | EP | claimed |
| WO-2009075874-A1 | GAMMA SECRETASE MODULATORS | AMGEN INC. (US) | 2009-06-18 | — | — | WO | claimed |
| EP-4192816-A1 | COMPOUNDS AS C5AR INHIBITORS | Kira Pharmaceuticals (Suzhou) Ltd. (CN) | 2023-06-14 | — | — | EP | disclosed |
| US-9567355-B2 | Hepatitis C inhibitors and uses thereof | ABBVIE INC. (US) | 2017-02-14 | — | — | US | disclosed |
| US-20160355530-A1 | HEPATITIS C INHIBITORS AND USES THEREOF | ABBVIE INC. | 2016-12-08 | — | — | US | disclosed |
| US-9453007-B2 | Hepatitis C inhibitors and uses thereof | ABBVIE INC. (US) | 2016-09-27 | — | — | US | disclosed |
| US-20160002213-A1 | HEPATITIS C INHIBITORS AND USES THEREOF | ABBVIE INC. | 2016-01-07 | — | — | US | disclosed |
| US-9173887-B2 | Hepatitis C inhibitors and uses thereof | ABBVIE INC. (US) | 2015-11-03 | — | — | US | disclosed |
| US-20140038919-A1 | HEPATITIS C INHIBITORS AND USES THEREOF | ABBVIE INC. (US) | 2014-02-06 | — | — | US | disclosed |
| US-20110166132-A1 | Gamma Secretase Modulators | AMGEN INC. (US) | 2011-07-07 | — | — | US | disclosed |
| EP-2231602-A1 | GAMMA SECRETASE MODULATORS | Amgen, Inc (US) | 2010-09-29 | — | — | EP | disclosed |
| WO-2009075874-A1 | GAMMA SECRETASE MODULATORS | AMGEN INC. (US) | 2009-06-18 | — | — | WO | disclosed |
| US-4098760-A | NON-MIGRATORY, NON-LEACHING | UNIROYAL, INC. (US) | 1978-07-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160002213-A1 | HEPATITIS C INHIBITORS AND USES THEREOF | HAVCR2, HCCS, SLC10A1 | MAPT 4059/4885GAA 288/4885LMNA 1618/4885 |
| US-20140038919-A1 | HEPATITIS C INHIBITORS AND USES THEREOF | HAVCR2, HCCS, SLC10A1 | MAPT 4059/4885GAA 288/4885LMNA 1618/4885 |
| US-20110166132-A1 | Gamma Secretase Modulators | BACE1, BACE2, PSEN1 | MAPT 173/4885GAA 11/4885LMNA 1416/4885 |
| US-20160355530-A1 | HEPATITIS C INHIBITORS AND USES THEREOF | HAVCR2, HCCS, SLC10A1 | MAPT 4059/4885GAA 288/4885LMNA 1618/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.